Exagen Inc (XGN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
$7.31+0.14%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
Intact: The reason to own it still holds.
Exagen aims for $70M to $73M revenue in 2026. Revenue grew from $16.6M to $17.3M in Q1. Operating loss improved from -$4.98M to -$3.41M in Q1. Cost control and revenue growth show progress.
Exagen is still losing money and cash flow worsened in Q1. Revenue growth is slow. The company missed earnings several times recently.
The market expects about 11% revenue growth. Our fair value is much higher than the Street median, showing optimism beyond consensus.
Breaks if: Cash flow worsens beyond -$10M
Improve cash flow from operating activities to support financial stability and reduce cash burn.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a turnaround situation. XGN is currently loss-making but is showing signs of progress in revenue growth and reducing operating losses, although risks remain elevated.
The market seems to price in a low level of fragility, with XGN being viewed as justified compared to peers. The valuation is considered cheap against its industry, indicating that expectations may be lower than what could be achieved if management executes effectively.
Management is focused on achieving full-year revenue targets and improving operating income, with recent results showing a positive trajectory in revenue growth. However, cash flow from operations remains negative, indicating mixed progress.
The thesis hinges on management's ability to meet revenue guidance and improve operating income. Additionally, external factors such as sector performance and macroeconomic conditions, like job growth, will play a critical role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management stated this priority in 3 of last 3 quarters. Cash and cash equivalents declined from $30 million in 2025-Q4 to $24.6 million in 2026-Q2, while cash from operations improved from negative $10.4 million in 2026-Q1 to negative $3.0 million in 2026-Q2. The trajectory shows partial progress but cash flow remains negative, indicating mixed delivery.
“Ended the quarter with approximately $25 million in cash and cash equivalents.”
“Ended the quarter with approximately $22 million in cash and cash equivalents.”
“Cash and cash equivalents were $30 million at year end.”
Breaks if: Operating loss worsens beyond -$5M
Focus on improving operating income through cost management and revenue growth.
Breaks if: Revenue falls below $66M in FY26
Over the next 1 to 3 years, XGN's performance will depend on management execution and broader market conditions. Not investment advice.